Atai Life Sciences: RL-007, Targeting Schizophrenia Subpopulation
DarioGaona/iStock via Getty Images Atai Life Sciences (NASDAQ:ATAI) has been making great progress in advancing several drugs from its pipeline on multiple fronts. In particular, it is advancing a clinical candidate known as RL-007 for the treatment of patients with cognitive impairment associated with schizophrenia, in an ongoing phase 2b study. Top-line results from this…